1. Abigail, Ezekiel, and Freireich Mike Martin, MD My last Grand Rounds 12/19/8 2. CAVEAT 1:MY ROLE IN THIS PRESENTATION IS TO BE IMPARTIALCAVEAT 2:WITHOUT YOUR COMMENTS,…

Slide 1New Strategies on Horizon Tony Mok MD Dept of Clinical Oncology The Chinse University of Hong Kong Slide 2 TKI is forever Addressing the difference Novel Target Slide…

1. Lung cancer • Early lung cancer: Surgery & Radiosurgery have similar results • However, NO level I evidence regarding role of Surgery or SBRT in early NSCLC •…

1. New Perspectives on Second-Line Therapy for NSCLC Tony Mok, MD (Moderator) Professor, Department of Clinical Oncology, Chinese University of Hong Kong; Honorary Consultant,…

Slide 1Questions and answers about PARAMOUNT: phase III study of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC. Slide 2 All questions at a glance:…

Slide 1Simon K. Cheng 1, Kevin Stephenson 2, Lynn Shi 2, Kunal Chaudhary 1, Anshu Jain 1, David P. Horowitz 1, Sherry X. Yan 2, Tony Wang 1, Clifford Chao 1, Tom K. Hei 1…

Slide 1 Acquired Resistance Patient Forum September 6, 2014 | Boston In ALK, ROS1 & EGFR Lung Cancers Clinical trial design and development of highly targeted agents…

Seeing Beyond Age in the Management of Advanced Lung Cancer Patient Case 1: Presentation Patient Case 1: Diagnosis IFCT-0501 Trial of Platinum-Doublet vs Single Agent Chemo…

Giovanni L. Pappagallo ([email protected]) MULTIPLE TREATMENT CHOICES: ARE THEY EQUALLY (cost) EFFECTIVE? YOUR TREATMENT CHOICE… Statistical Significance vs Clinical…

Personalized Therapy of Lung Cancer 2011 Winter Lung Cancer Conference Thomas J. Lynch, Jr., M.D. Jonathan and Richard Sackler Professor of Internal Medicine Director, Yale…